This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1(original).   An immunogenic conjugate comprising at least one vascular endothelial growth factor (VEGF) peptide moiety coupled to a carrier.

2(original). A conjugate according to claim 2 for use in therapy or prophylaxis.

3(currently amended). A conjugate as claimed in ~~either one of claims 1 or 2~~ claim 1 for combatting tumours and tumour metastasis.

4(currently amended). A conjugate as claimed in ~~any one of the preceding claims~~ claim 1 wherein said VEGF peptide moiety comprises an amino acid sequence having at least 80% homology with the whole or a section of a native VEGF sequence.

5(original). A conjugate as claimed in claim 4 wherein said section of a native VEGF sequence is a section of 8 to 100 amino acids.

6(original). A conjugate as claimed in claim 4 wherein said section of a native VEGF sequence is a section of 12 to 25 amino acids.

7(original). A conjugate as claimed in claim 4 wherein said degree of homology is with a section of a native VEGF sequence overlapping, abutting or adjacent a glycosylation site.

8(original). A conjugate as claimed in claim 7 wherein said section includes at least 12 of the first 16 amino acid residues from said glycosylation site in the N-terminal direction.

- 3 -

9(currently amended). A conjugate as claimed in ~~any one of the preceding claims~~ claim 1 wherein the VEGF peptide moiety comprises an oligopeptide comprising at least part of SEQ ID No. 1: TEESNITMQÍ MRIKPHQGQH IGEMSFLQHN.

10(currently amended). A conjugate as claimed in ~~any one of the preceding claims~~ claim 1 wherein the VEGF peptide moiety comprises an oligopeptide of formula:

$$(T)_a (M)_b (Q)_c (I)_d MRIKPHQGQ (H)_e (I)_f (G)_g (E)_h (M)_i (S)_j (F)_k (L)_l (Q)_m$$

where:
- a to m are each 0 or 1
- but a to c and f to m may not be 1 unless the sequence so created corresponds to a sequence in SEQ ID No. 1
- e to g are 1

11(original). A conjugate as claimed in claim 10 wherein e to j are 1.

12(currently amended). A conjugate as claimed in ~~any one of the preceding claims~~ claim 1 wherein said VEGF peptide moiety is coupled via its N-terminal end to the carrier.

13(currently amended). A conjugate as claimed in ~~any one of the preceding claims~~ claim 1 where said carrier is selected from the group consisting of the purified protein derivative of tuberculin, tetanus toxoid, diptheria toxoid, keyhole limpet haemocyanin, glutathione S-transferase and derivatives thereof.

14(currently amended). The use of an immunogenic conjugate as claimed in ~~any one of claims 1 to 13~~ claim 1 comprising at least one vascular endothelial growth factor peptide moiety coupled to a carrier for the manufacture of a medicament for use in combatting tumours.

15(original). A vascular endothelial growth factor derivative comprising at least one VEGF peptide moiety coupled to a peptide carrier-binding moiety.

16(original). A nucleic acid molecule coding for a vascular endothelial growth factor derivative comprising at least one VEGF peptide moiety coupled to a peptide carrier-binding moiety according to claim 15, and nucleic acid molecules with sequences complementary thereto.

17(original). An expression vector comprising a nucleic acid molecule according to claim 16.

18(currently amended). A pharmaceutical composition comprising a conjugate according to ~~any one of claims 1 to 13~~ claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

19(currently amended). A method of combatting tumours in a human or non-human subject comprising administering to said subject an effective amount of a conjugate as defined in ~~any one of claims 1 to 13~~ claim 1.

20(currently amended). A method for achieving maximal blockade of VEGF in a human or non-human subject comparable to or exceeding that achieved by chemo- or radiotherapy, said method comprising administering to said subject an effective amount of a VEGF conjugate as claimed in ~~any one of claims 1 to 13~~ claim 1.